The Technical Analyst
Cohen & Steers Global [GRI]
Exchange: ETF
Cohen & Steers Global Price, Forecast, Insider, Ratings, Fundamentals & Signals
-2.66% $0.424
America/New_York / 1 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1.356 mill |
| EPS: | -28.25 |
| P/E: | -0.0200 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 3.20 mill |
| Avg Daily Volume: | 0.413 mill |
| RATING 2024-05-01 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 1/24 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0200 | sector: PE -6.11 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.0200 | industry: PE -6.11 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.340 - 0.508 ( +/- 19.81%) |
| ATR Model: 14 days |
Forecast:
16:00 - $0.411
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.411
Forecast 2: 16:00 - $0.411
Forecast 3: 16:00 - $0.411
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.424 (-2.66% ) |
| Volume | 0.0872 mill |
| Avg. Vol. | 0.413 mill |
| % of Avg. Vol | 21.08 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GRI
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
GRI
GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that is developed as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was incorporated in 2009 and is based in LA Jolla, California.
Latest Press Releases
2024-04-29 08:45:00 - Press Release
Gri Bio Announces Abstracts Accepted For Presentation At The 14th International Congress On Autoimmunity
La jolla, ca, april 29, 2024 (globe newswire) -- gri bio, inc. (nasdaq: gri) (“gri bio” or the “company”), a biotechnology company advancing an innovative pipeline of natural killer t (nkt) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstracts have been accepted for presentation at the 14 th international congress on autoimmunity being held may 17-20, 2024 in ljubljana, slovenia.
2024-04-25 09:15:00 - Press Release
Gri Bio To Present At Live! With Webull Corporate Connect: Virtual Biotech Investment Webinar
Live webcast on wednesday, may 1 st at 3:00 pm et la jolla, ca, april 25, 2024 (globe newswire) -- gri bio, inc. (nasdaq: gri) (“gri bio” or the “company”), a biotechnology company advancing an innovative pipeline of natural killer t (nkt) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that marc hertz, phd, chief executive officer of gri bio, will present at live! with webull corporate connect: virtual biotech investment webinar on wednesday, may 1, 2024 at 3:00 pm et.
2024-04-16 08:35:00 - Press Release
Gri Bio Expands Intellectual Property Protection For Proprietary Natural Killer T (nkt) Cell Modulators With Issuance Of Korea Patent
Ongoing efforts to build a robust global patent estate for a growing pipeline targeting high-value indications in need of innovation
2024-04-08 08:35:00 - Press Release
Gri Bio Announces Abstract Accepted For Poster Presentation At The 2024 American Thoracic Society International Conference
La jolla, ca, april 08, 2024 (globe newswire) -- gri bio, inc. (nasdaq: gri) (“gri bio” or the “company”), a biotechnology company advancing an innovative pipeline of natural killer t (nkt) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been accepted for poster presentation at the 2024 ats international conference being held may 17-22, 2024 in san diego, ca.
2024-04-01 07:35:00 - Press Release
Gri Bio Reports Full Year 2023 Financial Results And Provides Corporate Update
Ongoing phase 2a biomarker study evaluating lead program gri-0621 for the treatment of idiopathic pulmonary fibrosis (ipf) with interim data expected h1 2024 and topline data expected h2 2024
Latest News
2024-04-25 09:15:00 - GlobeNewsWire
GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Live webcast on Wednesday, May 1 st at 3:00 PM ET LA JOLLA, CA, April 25, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, May 1, 2024 at 3:00 PM ET.
2024-03-28 09:00:00 - GlobeNewsWire
GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference
Live webcast on Wednesday, April 3 rd at 10:10 AM ET LA JOLLA, CA, March 28, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will present at the MedInvest Biotech & Pharma Investor Conference being held in New York City, NY on Wednesday, April 3, 2024 at 10:10 AM ET. In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
2024-02-02 08:55:50 - InvestorPlace
Why Is GRI Bio (GRI) Stock Down 21% Today?
GRI Bio (NASDAQ: GRI ) stock is taking a beating on Friday as investors in GRI react to the pricing of a public offering for the biotechnology company's shares. According to a press release from GRI Bio, this public offering includes 5 million shares of GRI stock priced at $1.10 each.
2023-09-06 09:05:00 - GlobeNewsWire
GRI Bio to Present at the H.C. Wainwright 25th Annual Global Investment Conference
LA JOLLA, CA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY and virtually.
2023-07-24 09:00:00 - GlobeNewsWire
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor – The GRI Opportunity Spotlight Event
- Live moderated webcast with members of the GRI Bio management team on Thursday, July 27 th at 1:00 PM ET
2023-06-15 08:45:00 - GlobeNewsWire
GRI Bio (NASDAQ: GRI) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
